Cowealth Medical China Co.,Ltd. (SHA:603122)
China · Delayed Price · Currency is CNY 12.37
+0.39 (3.26%)
At close: Sep 1, 2026
Cowealth Medical China Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,924 | 9,712 | 2,790 | 3,204 | 4,458 | - | |
Market Cap Growth | 87.42% | 248.07% | -12.92% | -28.13% | - | - |
Enterprise Value | 4,828 | 9,547 | 2,712 | 3,076 | 4,347 | - |
Last Close Price | 12.37 | 24.40 | 6.88 | 7.81 | 10.67 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 101.22 | 67.91 | 53.90 | - |
PS Ratio | 7.59 | 14.33 | 2.97 | 2.93 | 3.48 | - |
PB Ratio | 4.73 | 9.17 | 2.38 | 2.74 | 3.78 | - |
P/TBV Ratio | 4.77 | 9.24 | 2.40 | 2.77 | 3.79 | - |
P/FCF Ratio | - | 2795.48 | 27.65 | - | - | - |
P/OCF Ratio | - | 549.35 | 21.02 | 284.04 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.44 | 14.09 | 2.89 | 2.82 | 3.40 | - |
EV/EBITDA Ratio | - | - | 64.32 | 42.93 | 40.66 | - |
EV/EBIT Ratio | - | - | 77.34 | 47.71 | 43.97 | - |
EV/FCF Ratio | - | 2747.99 | 26.87 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.06 | 0.04 | 0.06 | 0.07 | 0.17 |
Debt / EBITDA Ratio | - | - | 1.15 | 0.94 | 0.73 | 1.13 |
Debt / FCF Ratio | - | 17.64 | 0.50 | - | - | - |
Net Debt / Equity Ratio | -0.09 | -0.08 | -0.18 | -0.11 | -0.22 | -0.02 |
Net Debt / EBITDA Ratio | 2.95 | 2.61 | -4.99 | -1.77 | -2.40 | -0.14 |
Net Debt / FCF Ratio | 1.47 | -25.37 | -2.08 | 2.24 | 4.56 | 1.03 |
Asset Turnover | 0.43 | 0.46 | 0.64 | 0.72 | 0.96 | 1.07 |
Inventory Turnover | 3.07 | 3.11 | 3.83 | 4.33 | 5.34 | 5.91 |
Quick Ratio | 2.29 | 2.36 | 3.17 | 3.38 | 3.01 | 2.36 |
Current Ratio | 2.96 | 3.06 | 4.05 | 4.39 | 3.90 | 3.22 |
Return on Equity (ROE) | -3.13% | -3.02% | 2.43% | 4.02% | 8.38% | 10.60% |
Return on Assets (ROA) | -1.68% | -1.77% | 1.48% | 2.67% | 4.61% | 5.75% |
Return on Invested Capital (ROIC) | -4.14% | -4.27% | 2.52% | 4.71% | 8.44% | 10.94% |
Return on Capital Employed (ROCE) | -3.90% | -3.90% | 3.00% | 5.50% | 8.30% | 12.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.69% | -0.35% | 0.99% | 1.47% | 1.85% | - |
FCF Yield | -1.36% | 0.04% | 3.62% | -1.77% | -1.26% | - |
Dividend Yield | 1.10% | - | 1.89% | 0.77% | 1.41% | - |
Payout Ratio | - | - | 97.75% | 138.28% | 90.11% | 99.28% |
Buyback Yield / Dilution | -8.98% | -6.79% | -0.15% | -4.58% | -26.53% | 1.71% |
Total Shareholder Return | -7.88% | -6.79% | 1.74% | -3.81% | -25.13% | 1.71% |